GlassScriptPhysician profile
Kyle K Wells
NPI 1831682293
$1,248.44
in general payments reported to CMS, 2019-2025
18 companies · $49.01 in 2025
The $49.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $14.38 · 2021: $68.18 · 2022: $314 · 2023: $386 · 2024: $317 · 2025: $49.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $239.71 | 2021-2024 | Otezla, Repatha, Evenity |
| Abbvie INC. | $176.71 | 2022-2023 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $128.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.44 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $98.04 | 2021-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $77.13 | 2022-2025 | Airsupra, Flumist Quadrivalent |
| Pfizer INC. | $51.01 | 2023 | |
| Glaxosmithkline, LLC. | $50.97 | 2022 | |
| Mylan Specialty L.P. | $46.25 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $42.07 | 2023-2024 | Cologuard Collection Kit |
| Organogenesis INC. | $40.30 | 2024 | Puraply Am |
| Novartis Pharmaceuticals Corporation | $33.60 | 2022-2025 | |
| Ibsa Pharma INC. | $31.55 | 2024 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $30.51 | 2022 | |
| Xeris Pharmaceuticals, INC. | $28.92 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.38 | 2020 | |
| Indivior INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.